Last reviewed · How we verify
NCT03797521: TTM
A Study in Patients With Trichotillomania
Phase 2 trial testing SXC-2023 in Trichotillomania in 128 participants. Completed in 16 December 2019.
2 December 2019
Quick facts
| Lead sponsor | Promentis Pharmaceuticals, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 128 |
| Start date | 19 December 2018 |
| Primary completion | 2 December 2019 |
| Estimated completion | 16 December 2019 |
| Sites | 13 locations across United States |
Drugs / interventions tested
- SXC-2023 — full drug profile →
- Placebo
Conditions studied
- Trichotillomania — all drugs for Trichotillomania →
Sponsor
Promentis Pharmaceuticals, Inc. — full company profile →
Who can join
Adults 18 to 45, any sex, with Trichotillomania. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to explore the safety, tolerability and activity of SXC-2023 when dosed for 6 weeks versus placebo in adult patients with moderate to severe Trichotillomania.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Ferroptosis and endoplasmic reticulum stress in rheumatoid arthritis.
Ao Q, Hu H, Huang Y. · · 2024 · cited 25× · PMID 39076977 · DOI 10.3389/fimmu.2024.1438803 -
Pharmacotherapy for trichotillomania.
Hoffman J, Williams T, Rothbart R, Ipser JC, et al · · 2021 · cited 14× · PMID 34582562 · DOI 10.1002/14651858.cd007662.pub3
Verify or expand the search:
- PubMed search for NCT03797521
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SXC-2023
Trials testing the same drug.
- NCT06343532 — SXC-2023 Cocaine Interaction Study · Phase 1 · completed
- NCT03887429 — Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal · Phase 2 · completed
- NCT03542435 — Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC · Phase 1 · completed
- NCT03301298 — Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers · Phase 1 · completed
Other recruiting trials for Trichotillomania
Currently open trials in the same condition.
- NCT07224126 — Technology Assisted Treatment of Trichotillomania: Open Trial · NA · recruiting
- NCT02747771 — Cognitive Behavioral Group Therapy for Trichotillomania (Hair Pulling Disorder) · recruiting
Other Promentis Pharmaceuticals, Inc. trials
Trials by the same sponsor.
- NCT03887429 — Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal · Phase 2 · completed
- NCT03542435 — Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC · Phase 1 · completed
- NCT03301298 — Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03797521 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Promentis Pharmaceuticals, Inc.
- Last refreshed: 28 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03797521.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing